Wyeth Pharmaceuticals, una división de Wyeth tiene productos líderes en el área de salud de la mujer, enfermedad cardiovascular, sistema nervioso central, inflamación, trasplante, hemofilia, oncología, vacunas y productos nutricionales. Wyeth es una de las mayores empresas farmacéuticas y de productos sanitarios del mundo. La compañía es una de las firmas líderes en el descubrimiento, desarrollo, fabricación y comercialización de productos farmacéuticos, vacunas, biotecnología y medicinas genéricas que mejoran la calidad de las personas de todo el mundo. Las principales divisiones de Wyeth son Wyeth Pharmaceuticals, Wyeth Consumer Healthcare y Fort Dodge Animal Health.
Data on file. A multicenter, open label study to observe the effect of entanercept on joint and skin disease on subjects with psoriatic arthritis (EDUCATE), Amgen.
2. Jackson JM et al Psoriatic Arthritis Patients Treated with Etanercept Had Reductions in Health Care Resource Utilization - Results from the Experience Diagnosing, understanding Care , and Treating with Etanercept (EDUCATE) Trial, Abstract P2781. Presented at the American Academy of Dermatology; March 3-7, 2006; New Orleans, LA, USA.
3. Sobell J et al, Psoriatic Arthritis Patients Treated with Etanercept Report Reductions in Caregiver Burden and Absenteeism - Results from the Experience Diagnosing, understanding Care , and Treating with Etanercept (EDUCATE) Trial. Abstract - 2782. Presented at the American Academy of Dermatology; March 3-7, 2006; New Orleans, LA, USA.
4. Christophers E. Psoriasis in epidemiology and clinical spectrum, Clin Exp Dermatol. 2001;26:314-320.
5. Zachariae H, Zachariae R., Blomqvist K, et al.Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic psoriasis associations. Acta Derm Venerol. 2002; 82: 108-113.
6. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.Arch Dermatol.2001;137:280-284
7. Gladman D.D et al. Psoriatic Arthritis (PSA) - An Analysis of 220 Patients, Quarterly Journal of Medicine, new series 62, No. 238 pp.127-141, February 1987
Para más información contacte con: Peter O'Brien, Wyeth Pharmaceuticals, oficina:+353-1-4694707, móvil:+353(87)8114637, Email: obrienp7@wyeth.com; Ketchum, Jes Lauritzen , oficina: + 44(0)20-7611-3650, móvil : +44(0)7962-44-55-25 Email: jes.lauritzen@ketchum.com
